Together, we can transform the future of cancer care.
Tracking early stage breast cancer with ultrasensitive ctDNA
Information for patients with breast cancer
Monitoring therapy response with ultrasensitive ctDNA across cancer types
Ultrasensitive ctDNA detection in early-stage lung cancer
Personalis is transforming the development of next-generation therapies.
Early Access Program – Limited Availability
NeXT Personal® Dx showed up to 4X higher sensitivity for pre-operative ctDNA detection in LUAD patients compared to non-Personalis, previous generation assays.
NeXT Personal® Dx detected ctDNA recurrence with a median lead time of 6 months compared to radiographic imaging.
Strong PPV of 94%, NPV of 89% for recurrence with serial testing over a median follow-up of 5 years in early-stage NSCLC patients.
Abbreviations: LUAD, lung adenocarcinoma; NSCLC, non-small cell lung cancer; NPV, negative predictive value; PPV, positive predictive value *All assays were used to analyze patients from the TRACERx cohort, but the specific patients analyzed by each assay may differ.
Dr. James R. Black, MD, from UCL, London, UK and Dr. Richard Chen, MD, MS, Chief Medical Officer at Personalis discuss NeXT Personal and clinical implications based on new ESMO data. Lung TRACERx is one of the most robust prospectively collected observational ctDNA studies for early-stage non-small cell lung cancer (NSCLC) with 170+ patients in the NeXT Personal cohort collected with median 5 years of follow-up, analyzed retrospectively.
*All assays were used to analyze patients from the TRACERx cohort, but the specific patients analyzed by each assay may differ.
PRO-1152-v1
This test is a laboratory developed test (LDT) and is performed in the CAP accredited, CLIA-certified Personalis Clinical Laboratory. The test was developed, and its performance characteristics determined by the Personalis Clinical Laboratory. It has not been cleared or approved by the United States Food and Drug Administration (FDA).
Clinical samples submitted in the form of isolated or extracted nucleic acids will only be accepted if the isolation of nucleic acids occurs in a CLIA-certified laboratory or a laboratory meeting equivalent requirements as determined by the CAP and/or the CMS.